Vectus Biosystems Ltd
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue t… Read more
Vectus Biosystems Ltd (VBS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 2.572x
Based on the latest financial reports, Vectus Biosystems Ltd (VBS) has a cash flow conversion efficiency ratio of 2.572x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-659.98K) by net assets (AU$-256.62K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vectus Biosystems Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Vectus Biosystems Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Vectus Biosystems Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vectus Biosystems Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NorCom Information Technology GmbH & Co. KGaA
XETRA:NC5A
|
0.063x |
|
Megalestari Epack Sentosaraya Pt
JK:EPAC
|
0.086x |
|
DF Deutsche Forfait AG
XETRA:DFTK
|
0.101x |
|
AST Groupe
PA:ALAST
|
-0.811x |
|
Focus Universal Inc
NASDAQ:FCUV
|
-6.068x |
|
PALATIN TECHS DL-01
F:PTN
|
N/A |
|
Traka Resources Ltd
AU:TKL
|
6.791x |
|
MMEX Resources Corp
PINK:MMEX
|
0.007x |
Annual Cash Flow Conversion Efficiency for Vectus Biosystems Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of Vectus Biosystems Ltd from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$-256.62K | AU$-830.09K | 3.235x | +336.52% |
| 2024-06-30 | AU$1.49 Million | AU$-2.03 Million | -1.368x | -104.82% |
| 2023-06-30 | AU$3.52 Million | AU$-2.35 Million | -0.668x | -166.48% |
| 2022-06-30 | AU$-4.42 Million | AU$-4.44 Million | 1.004x | -10.54% |
| 2021-06-30 | AU$-2.90 Million | AU$-3.26 Million | 1.123x | +151.03% |
| 2020-06-30 | AU$-6.71 Million | AU$-3.00 Million | 0.447x | +60.32% |
| 2019-06-30 | AU$-3.73 Million | AU$-1.04 Million | 0.279x | -54.62% |
| 2018-06-30 | AU$-2.26 Million | AU$-1.39 Million | 0.615x | +101.84% |
| 2017-06-30 | AU$116.56K | AU$-3.89 Million | -33.399x | -4696.01% |
| 2016-06-30 | AU$3.75 Million | AU$-2.61 Million | -0.696x | -376.09% |
| 2015-06-30 | AU$11.22 Million | AU$-1.64 Million | -0.146x | +99.37% |
| 2014-06-30 | AU$55.53K | AU$-1.29 Million | -23.292x | -1926.15% |
| 2013-06-30 | AU$976.04K | AU$-1.12 Million | -1.150x | -141.21% |
| 2012-06-30 | AU$-504.57K | AU$-1.41 Million | 2.789x | -- |